Covid 19 Research Clinical Trials by Shray Alag

CUROSURF® (poractant alfa)

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (3)

	Name (Synonyms)	Correlation
drug3628	Simvastatin Wiki	0.71
drug356	Aspirin Wiki	0.50
drug2176	Losartan Wiki	0.33

Correlated MeSH Terms (4)

	Name (Synonyms)	Correlation
D013577	Syndrome NIH	0.09
D012127	Respiratory Distress Syndrome, Newborn NIH	0.08
D055371	Acute Lung Injury NIH	0.08

	Name (Synonyms)	Correlation
D012128	Respiratory Distress Syndrome, Adult NIH	0.07

Correlated HPO Terms (0)

	Name (Synonyms)	Correlation

Clinical Trials

Navigate: Correlations HPO

There is one clinical trial.

1 Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)

The purpose of this Phase II -Proof of Concept study is to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in adult hospitalized patients with SARS-COV-19 acute respiratory distress syndrome (ARDS)

NCT04502433

Conditions

Acute Respiratory Distress Syndrome

Interventions

Drug: CUROSURF® (poractant alfa)

MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Description: The primary outcome variable will be the number of ventilator-free days, defined as the number of days the patient is not receiving mechanical ventilation during the 21 days following randomisation.

Measure: number of ventilator-free days

Time: up to 21 days

Secondary Outcomes

Measure: Number of free days from invasive ventilation

Time: up to 21 days

Measure: Number of free days from non-invasive ventilation (NIV)

Time: up to 21 days

Measure: Change from baseline in PaO2/FiO2 ratio measured at 6 hours and 12 hours following administration of each dose in the treated group and at the similar timepoints in the control group

Time: 6, 12, 30, 36, 54 and 60 hours after randomisation

Measure: Change from baseline in PaO2/FiO2 ratio at additional timepoints

Time: every 24 hours after treatment/randomisation until the patient is discharged from the ICU . Up to 28 days

Measure: Length of ICU stay (days)

Time: up to 28 days

Measure: Mortality at Day 28

Time: Day 28

Measure: Change from baseline in ventilatory parameter (Tidal volume (TV))

Time: up to 28 days

Description: min score 0 max score 24

Measure: Delta Sequential Organ Failure Assessment (SOFA) Score

Time: up to 28 days

Measure: Incidence of all the AEs, AEs related to poractant alfa (treated cohort) (ADRs), serious AEs (SAEs) and AEs leading to death

Time: up to 28 days

Measure: Change from baseline in blood gas analysis acid-base balance parameter (pH)

Time: up to 28 days

Measure: Percentage of patients with PaO2/ FiO2 improvement of >20% following administration of each dose in the treated group and at similar timepoints in the control group

Time: at 6 and 12 hours following administration each dose in the treated group and at similar timepoints in the control group = up to 60 hours after the randomization

Measure: Number of Extracorporeal Membrane Oxygenation (ECMO)-free days- (only for cohort 2 of patients in ECMO)

Time: 21 days after randomization

Measure: Change from baseline in FiO2

Time: (6, 12, 30, 36, 54 and 60 hours after randomisation + every 24 hours after treatment/randomisation until the patient is discharged from the ICU = up to 28 days

Measure: Change from baseline in ventilatory parameter (respiratory rate (RR))

Time: up to 28 days

Measure: Change from baseline in ventilatory parameter (dynamic compliance (Cdyn))

Time: up to 28 days

Measure: Change from baseline in ventilatory parameter (static compliance (Cstat))

Time: up to 28 days

Measure: Change from baseline in ventilatory parameter (positive end-expiratory pressure (PEEP)

Time: up to 28 days

Measure: Change from baseline in ventilatory parameter (peak inspiratory pressure (PIP))

Time: up to 28 days

Measure: Change from baseline in ventilatory parameter (plateau pressure (Pplat))

Time: up to 28 days

Measure: Change from baseline in blood gas analysis acid-base balance parameter (pCO2)

Time: up to 28 days

Measure: Change from baseline in blood gas analysis acid-base balance parameter (pO2)

Time: up to 28 days

Measure: Change from baseline in blood gas analysis acid-base balance parameter (HCO3)

Time: up to 28 days

Measure: Change from baseline in blood gas analysis acid-base balance parameter (lactate)

Time: up to 28 days

No related HPO nodes (Using clinical trials)

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

No related HPO nodes (Using clinical trials)

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

CovidResearchTrials

Report Sections

See All Reports

CUROSURF® (poractant alfa)

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (3)

Correlated MeSH Terms (4)

Correlated HPO Terms (0)

Clinical Trials

1 Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)

NCT04502433

Conditions

Interventions

MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

Report Sections

See All Reports

CUROSURF® (poractant alfa)

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (3)

Correlated MeSH Terms (4)

Correlated HPO Terms (0)

Clinical Trials

1 Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS) Click for details

NCT04502433

Conditions

Interventions

MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

1 Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)